Krka DDLTS:0HLK 78 Net Margin % is 21.38% as of Mar. 2026, which is 19% above its 10-year median of 18.04. GuruFocus rates LTS:0HLK with a GF Score™ of 78/100 and a GF Value™ of €38.09 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 953 Drug Manufacturers companies, Krka DD ranks better than 84.37% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Krka DD's Net Income for the
three
months ended in Mar. 2026 was €121 Mil. Krka DD's Revenue for the
three
months ended in Mar. 2026 was €566 Mil. Therefore, Krka DD's net margin for the quarter that ended in Mar. 2026 was 21.38%.
The historical rank and industry rank for Krka DD's Net Margin % or its related term are showing as below:
LTS:0HLK'
s Net Margin % Range Over the Past 10 Years
Min: 9.23 Med: 18.04 Max: 21.15
Current: 17.85
LTS:0HLK's Net Margin % is ranked better than 84.37% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs LTS:0HLK: 17.85
Krka DD (LTS:0HLK) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Krka DD Net Margin % Related Terms
Krka DD Net Margin % Historical Data
* Premium members only.
The historical data trend for Krka DD's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HLK vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's Net Margin % distribution charts can be found below:
* The bar in red indicates where Krka DD's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krka DD (LTS:0HLK) has a Net Margin % of 21.38% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Krka DD and its competitors. This is 19% above median its historical median of 18.04. Over the past decade, Krka DD's Net Margin % has ranged from 9.23 to 21.15. According to the industry distribution chart, Krka DD ranks #149 out of 953 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Krka DD's Net Margin % too high?
Krka DD's current Net Margin % of 21.38% is 19% above median its 10-year median of 18.04. Over the past 10 years, this metric has ranged from a low of 9.23 to a high of 21.15. The Drug Manufacturers industry median Net Margin % is 5.69. Krka DD's value of 21.38% is 275.7% above this industry median. Based on the distribution chart, Krka DD ranks #149 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #149 out of 953 companies for Net Margin %. This places Krka DD in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. Krka DD's value of 21.38% is 275.7% above this benchmark. Historically, Krka DD's own Net Margin % has ranged from 9.23 to 21.15 over the past decade. While the company's 10-year median is 18.04 vs. the industry median of 5.69, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current Net Margin % of 21.38% is 275.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current Net Margin % is 21.38%, which is 19% above median its own 10-year median of 18.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (LTS:0HLK) is currently considered Significantly Overvalued. The stock's GF Value™ is €38.09, compared to a current price of €64.80 — trading 70.1% above its estimated fair value. The current Net Margin % is 21.38%, which is 19% above median its 10-year median of 18.04 and 275.7% above the Drug Manufacturers industry median of 5.69. Krka DD's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Krka DD (LTS:0HLK), the current Net Margin % is 21.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (LTS:0HLK) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €64.80 is trading 70.1% above its estimated GF Value™ of €38.09.
GuruFocus considers Krka DD to be Significantly Overvalued.
Key valuation signals for LTS:0HLK:
Net Margin %: 21.38% (19% above median its 10-year median of 18.04)
GF Value™: €38.09 vs. price of €64.80 (70.1% above fair value)
Industry Position: 275.7% above the Drug Manufacturers median (#149 of 953)
No single metric tells the full story. See the LTS:0HLK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
78GF Score
Get the complete analysis for LTS:0HLK
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HLK has been successfully added to your 
